Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study.
Sign Up to like & getrecommendations! Published in 2020 at "Translational lung cancer research"
DOI: 10.21037/tlcr-20-1214
Abstract: Background Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are increasing considered for the tailored management of resectable non-small cell lung cancer (NSCLC). This study aimed to analyze the survival and toxicity profile… read more here.
Keywords: icotinib; egfr mutation; adjuvant icotinib; mutation positive ... See more keywords